PRPO

Precipio Inc($PRPO) Director Sells from Personal Account, Buys More Through IRA as Financial Metrics Improve Amid Stock Volatility

04/04/2025 21:04

Small-cap diagnostic company Precipio Inc ($PRPO) is showing interesting insider trading patterns after its stock price surged in February and subsequently corrected. Of particular interest are board member Richard Sandberg's tax-efficient investment strategy and a recent symbolic purchase by the company's COO. Precipio, a healthcare solutions company specializing in blood cancer diagnostics, reported $18.53 million in revenue for 2024, representing 22% growth year-over-year. Notably, the company improved its net loss by 26.7% to $4.29 million, signaling progress toward profitability. The stock currently trades in the low $5 range, significantly below its February peak when it briefly surpassed $10. From February 19-21, the share price surged from $8.31 to $10.14 in just three days, before gradually declining to current levels. Amid this backdrop, board member Richard Sandberg's distinctive trading pattern stands out. On December 13, 2024, he sold 12,000 shares from his personal holdings at $6.20 per share (totaling $74,400) while simultaneously purchasing 15,000 shares at $5.80 per share (totaling $87,000) through his Roth IRA account. The Roth IRA is a tax-advantaged retirement account in the U.S., suggesting this transaction represents a tax optimization strategy. Effectively, Sandberg increased his share ownership by 3,000 shares, indicating a bet on the company's long-term growth potential. It's worth noting that his December purchase price of $5.80 per share is similar to current trading levels. Meanwhile, COO Ahmed Zaki Sabet made a small but symbolic purchase of 79 shares at $6.00 per share on April 2, 2025. While the total amount was just $473.75, the timing of this executive purchase during a downtrend carries symbolic significance. These insider transactions coincide with Precipio's improving financial situation. The company achieved positive adjusted EBITDA and cash flow in Q4 2024, with revenue of $5.45 million representing 4.6% growth from the previous quarter. Net loss decreased from $626,000 in Q3 to $365,000 in Q4. In June 2024, the company announced it expected its pathology division to reach breakeven in Q3 2024, and was improving its financial situation through short-term loans and reduced cash burn. Currently, Precipio has a low debt-to-equity ratio of 3.1% and holds $1.39 million in cash. However, short-term liabilities ($4.3 million) exceed short-term assets ($3.5 million), suggesting caution regarding short-term liquidity. Nevertheless, with improving cash burn rates and minimal long-term debt of just $631,000, the overall financial health appears reasonably sound. The mid-February stock surge lacks clear correlation to specific company announcements or insider transactions, suggesting it may have resulted from broader market factors or short-term investor interest. The recent price decline can be viewed as a correction to this short-term rise. Wall Street analysts note Precipio's consistent revenue growth and declining losses, while acknowledging that complete profitability will take time. With the general volatility in the biotech sector, the market expansion potential of Precipio's diagnostic product lineup (particularly IV-Cell and HemeScreen) will likely be key to medium and long-term growth. Investors should monitor whether revenue growth and loss reduction trends continue, particularly whether the pathology division achieves its breakeven target. Additionally, further share purchases by insiders, especially Director Sandberg and executives, will be important monitoring points.

You can receive notifications when news is published.